Antibody molecule for human GM-CSF receptor alpha
Binding members are provided for alpha chain of receptor for granulocyte macrophage colony stimulating factor (GM-CSFRα), especially antibody molecules. Use of the binding members in treating inflammatory and autoimmune diseases, e.g. rheumatoid arthritis, asthma, allergic response, multiple sclerosis, myeloid leukaemia and atherosclerosis is also provided.
1. An isolated antibody molecule for human GM-CSFRα, which inhibits binding of GM-CSF to GM-CSFRα, and which comprises a VH domain with the VH domain amino acid sequence shown in SEQ ID NO: 52 and a VL domain with the VL domain amino acid sequence shown in SEQ ID NO: 218.
2. The isolated antibody molecule according to claim 1 , wherein the antibody molecule is an IgG4.
3. An isolated antibody molecule, wherein the antibody molecule comprises an antibody VH domain and an antibody VL domain, the antibody VH domain comprising heavy chain complementarity determining regions (CDRs) HCDR1, HCDR2 and HCDR3 and the VL domain comprising light chain CDRs LCDR1, LCDR2 and LCDR3, wherein the amino acid sequences of the CDRs are:
HCDR1 SEQ ID NO: 3
HCDR2 SEQ ID NO: 4
HCDR3 SEQ ID NO: 55
LCDR1 SEQ ID NO: 8
LCDR2 SEQ ID NO: 9, and
LCDR3 SEQ ID NO: 60.
4. An antibody molecule according to claim 3 , which is a human or humanised antibody molecule.
5. An antibody molecule according to claim 3 , comprising antibody VH domain amino acid sequence SEQ ID NO: 52.
6. An antibody molecule according to claim 3 , comprising antibody VL domain amino acid sequence SEQ ID NO: 218.
7. An antibody molecule according to claim 3 , which is an IgG4.
8. An antibody molecule according to claim 7 , wherein the antibody molecule is a human IgG4 antibody molecule comprising VH domain amino acid sequence SEQ ID NO: 52 and VL domain amino acid sequence SEQ ID NO: 218.
9. An isolated antibody molecule for human GM-CSFRα, which inhibits binding of GM-CSF to GM-CSFRα, and which comprises:
a VH domain with the VH domain amino acid sequence shown in SEQ ID NO: 52, or comprises that VH domain with one or two conservative amino acid substitutions, and
a VL domain with the VL domain amino acid sequence shown in SEQ ID NO: 218, or comprises that VL domain with one or two conservative amino acid substitutions.
10. A composition comprising an antibody molecule according to any of claim 1 , 2 , 3 or 4 - 9 and a pharmaceutically acceptable excipient.